



October 8, 2024

**Acuitas' CSO Co-Authors Article in *Nature Communications* With Scientists from Duke University School of Medicine Durham and Perelman School of Medicine**

Acuitas' Chief Scientific Officer, Dr. Ying Tam, collaborated with scientists from Duke University School of Medicine Durham and Perelman School of Medicine to develop an mRNA vaccine platform that delivers two immunodominant influenza antigens, neuraminidase and hemagglutinin, encoded in a single open reading frame. In a single dose of a mRNA LNP vaccine incorporating four mRNAs encoding the neuraminidase and hemagglutinin proteins of four influenza viruses, this quadrivalent mRNA vaccine is effective and, in some cases, superior to a current, industry standard, inactivated virus vaccines in immunogenicity against all vaccine strains in both mouse and ferret models (*Nature Communications* 2024).

Please click [here](#) to read the publication.

-END-